Search results :

Irinotecan

More information: STITCH, PubChem (stereo-specific compound: 1) and possibly Wikipedia

ATC Code: L01XX19

Side effects

Options: Hide MedDRA Preferred Terms ,   display all 24 labels

MedDRA Preferred Term Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Alopecia Alopecia 16.8% - 72% x x x x x x x x x x x x x x x x x x x x
Diarrhoea Diarrhoea postmarketing, 1.6% - 88% x x x x x x x x x x x x x x x x x
Leukopenia Leukopenia 0% - 98.6% x x x x x x x x x x x x x x x x x x x
Nausea Nausea 2.1% - 86.2% x x x x x x x x x x x x x x x x x x x x
Pain Pain 2% - 61.5% x x x x x x x x x x x x x x x x x x x x
Abdominal pain Abdominal cramps 8.7% - 57% x x x x x x x x x x x x x x x x x x x
Abdominal pain 0.7% - 67.7% x x x x x x x x x x x x x x x x x x x x
Hyperhidrosis Sweating 0% - 57% x x x x x x x x x x x x x x x x x x x
Sweating increased x x x x x x x x x x x x x x
Visual impairment Visual disturbance 15% x
Asthenia Asthenia 4.2% - 76% x x x x x x x x x x x x x x x x x x x
Fatigue x
Gastrointestinal pain Abdominal pain 0.7% - 67.7% x x x x x x x x x x x x x x x x x x x x
Dermatitis Rash 0% - 46.1% x x x x x x x x x x x x x x x x x x x
Rash Rash 0% - 46.1% x x x x x x x x x x x x x x x x x x x
Hand rash x
Vomiting Vomiting postmarketing, 2.8% - 67% x x x x x x x x x x x x x x x x x x x x
Flatulence Flatulence 0% - 12.2% x x x x x x x x x x x x x x x x x x x
Lacrimation increased Lacrimation 12% x x x x x x x x x x x x x x
Salivary hypersecretion Salivation 11% x
Salivary hypersecretion x x x x x x x x x x x x x
Dyspepsia Dyspepsia 0% - 10.5% x x x x x x x x x x x x x x x x x x x
Miosis Miosis 10% x x x x x x x x x x x x x x
Insomnia Insomnia 0% - 19% x x x x x x x x x x x x x x x x x x x
Headache Headache 0.7% - 17% x x x x x x x x x x x x x x x x x x x
Body temperature increased Body temperature increased 0.4% - 45.4% x x x x x x x x x x x x x x x x x x x x
Back pain Back pain 1.6% - 14.5% x x x x x x x x x x x x x x x x x x x
Constipation Constipation 0.4% - 32.3% x x x x x x x x x x x x x x x x x x x x
Rhinitis Rhinitis 0% - 16% x x x x x x x x x x x x x x x x x x x
Anaemia Anaemia 2.1% - 98.6% x x x x x x x x x x x x x x x x x x x x
Chills Chills 0% - 14% x x x x x x x x x x x x x x x x x x x
Stomatitis Stomatitis 0.7% - 12% x x x x x x x x x x x x x x x x x x x
Decreased appetite Anorexia 0.7% - 55% x x x x x x x x x x x x x x x x x x x x
Febrile neutropenia Febrile neutropenia 0.7% - 14.6% x x x x x x x x x x x x x x x x x x x
Oedema Oedema 1% - 10% x x x x x x x x x x x x x x x x x x x
Flushing Flushing 0% - 11% x x x x x x x x x x x x x x x x x x x
Vasodilation procedure Vasodilation 0% - 11% x x x x x x x x x x x x x x x x x x
Abdominal distension Enlargement abdomen 0% - 10% x x x x x x x x x x x x x x x x x x x
Bradycardia Bradycardia 5% x x x x x x x x x x x x x
Dehydration Dehydration postmarketing, 4% - 15% x x x x x x x x x x
Dyspnoea Dyspnoea postmarketing, 0% - 22% x x x x x x x x x
Neutropenia Neutropenia 0% - 98.6% x x x x x x x x x x x x x x x x
Piloerection Piloerection 3% x
Mucosal inflammation Mucosal inflammation 1% - 76.3% x x x x x x x x x x x x x x x x x x x
Thrombocytopenia Thrombocytopenia 0% - 98.6% x x x x x x x x x x x x x x x x x x x x
Confusional state Confusional state 0% - 4.1% x x x x x x x x x x
Feeling abnormal Confusional state 0% - 4.1% x x x x x x x x x x
Malaise x x
Dizziness Dizziness 0% - 21.1% x x x x x x x x x x x x x x x x x x x
Syncope x x x x x x x x x x x
Neutropenic infection Neutropenic infection 0% - 2.2% x x x x x x x x x x x x x x x x x x
Somnolence Somnolence 1.3% - 9.4% x x x x x x x x x x x x x
Pneumonia Pneumonia 1% - 3.6% x x x x x x x x x x
Cough Cough 0% - 20.2% x x x x x x x x x x x x x x x x x x x
Cough increased x x
Haemorrhage Haemorrhage postmarketing, 1% - 5% x x x x x x x x x x x x x x x x x x x
Haemoglobin Haemorrhage postmarketing, 1% - 5% x x x x x x x x x x x x x x x x x x x
Hypotension Hypotension postmarketing, 0% - 11.4% x x x x x x x x x x x x x x x
Dermatitis exfoliative Dermatitis exfoliative 0% - 26.5% x x x x x x x x x x
Colitis Colitis postmarketing x x x x x x
Colitis ulcerative Colitis ulcerative postmarketing x x
Proctocolitis Colitis ulcerative postmarketing x x
Infection Infection postmarketing, 0% - 33.6% x x x x x x x x x x x x x x x x x x x x
Connective tissue disorder Connective tissue disorder postmarketing x x
Dysarthria Dysarthria postmarketing x x x x x x x x x x
Osteoarthritis Dysarthria postmarketing x x x x x x x x x x
Gastrointestinal disorder Gastrointestinal disorder postmarketing x x
Gastrointestinal haemorrhage Gastrointestinal haemorrhage postmarketing x x x x x x x x x x
Cardiac disorder Cardiac disorder postmarketing x
Hiccups Hiccups postmarketing x x x x x x
Hypersensitivity Hypersensitivity postmarketing x x x x x x x x x x x x
Hyponatraemia Hyponatraemia postmarketing x x x x x x x x x x x x x x x
Immune system disorder Immune system disorder postmarketing x x
Intestinal obstruction Intestinal obstruction postmarketing x x
Intestinal perforation Intestinal perforation postmarketing x x x x x x x x
Renal failure acute Renal failure acute postmarketing x x x x x x x x x
Lung disorder Lung disorder postmarketing x x x x x x x x x x x x
Mediastinal disorder Mediastinal disorder postmarketing x x
Megacolon Megacolon postmarketing x x x x x
Megacolon toxic postmarketing x x x
Muscle spasms Cramp muscle postmarketing x x x x x x x x x
Nervous system disorder Nervous system disorder postmarketing x x
Pancreatitis Pancreatitis postmarketing x x x x x x x x x x x x x x x
Paraesthesia Paraesthesia postmarketing x x x x x x x
Shock Shock postmarketing x x x x x x x x
Syncope x x x x x x x x x x x
Speech disorder Speech disorder postmarketing x x
Ulcer Ulcer postmarketing x x x x x x x x x x x
Colitis ischaemic Colitis ischaemic postmarketing x x x x x x
Lung infiltration Lung infiltration postmarketing x x x x x x x x
Sepsis Sepsis postmarketing x x x x x x x x x x x x x x x
Caecitis Caecitis postmarketing x x x x x x x x
Cholinergic syndrome Cholinergic syndrome postmarketing, 0% - 1.4% x x x x x x x x x x x x x x x x x x x x
Toxicity to various agents Cholinergic syndrome postmarketing, 0% - 1.4% x x x x x x x x x x x x x x x x x x x x
Anaphylactic shock Anaphylactoid reaction postmarketing x x x x x x x x x x x
Anaphylactoid reaction Anaphylactoid reaction postmarketing x x x x x x x x x x x
Neutropenic colitis Neutropenic enterocolitis postmarketing x x
Metastases to liver Metastases to liver postmarketing x x x x x x x x x x x x x
Hepatic cancer metastatic Metastases to liver postmarketing x x x x x x x x x x x x x
Hypovolaemia Hypovolaemia postmarketing x x
Lipase increased Lipase increased postmarketing x x x x x x x
Embolism Thromboembolic event postmarketing, 5.4% - 11.4% x x x x x x x x x x x x x x x x x
Ileus Ileus postmarketing x x x x x x x x x x x
Renal failure Renal impairment postmarketing x x x x x x x x x x
Renal impairment Renal impairment postmarketing x x x x x x x x x x
Angina pectoris Angina pectoris x x x x x x x
Arrhythmia Arrhythmia x x x x x x x x x x
Neoplasm malignant Neoplasm malignant x
Colon cancer Colon cancer x x x x x x x x
Cerebral infarction Cerebral infarction x x x x x x x
Sudden death Sudden death x x x x x x x
Extravasation Extravasation x
Fatigue Fatigue x
Cardiac arrest Cardiac arrest x x x x x x x
Hepatomegaly Hepatomegaly x x x x x x x x x
Hyperbilirubinaemia Hyperbilirubinaemia x x
Hypertension Hypertension x
Hypokalaemia Hypokalaemia x x
Orthostatic hypotension Orthostatic hypotension x x x x x x x x x x x x
Hypotension orthostatic symptomatic x
Ischaemia Ischaemia x x x x x x x x x
Jaundice Jaundice x x x x x x x x x x x
Lung neoplasm Lung neoplasm x x x x x x x x x x x x
Lymphopenia Lymphopenia x x x x x x x x x x x x x x x x x x
Myocardial infarction Myocardial infarction x x x x x x x
Acute coronary syndrome Myocardial infarction x x x x x x x
Neoplasm Neoplasm x x x x x x x x x x
Genetic polymorphism Genetic polymorphism x
Pulmonary embolism Pulmonary embolism x x x x x x x x
Anorectal disorder Rectal disorder x x
Cerebrovascular accident Cerebrovascular accident x x x x x x x
Syncope Syncope x x x x x x x x x x x
Loss of consciousness Syncope x x x x x x x x x x x
Blacked-out (not amnesia) x x
Thrombophlebitis Thrombophlebitis x x x x x x x x
Thrombosis Thrombosis x x x x x x x
Tumour lysis syndrome Tumour lysis syndrome x x
Upper respiratory tract infection Upper respiratory tract infection x x x x x x x x x
Angiopathy Angiopathy x x x x x x x
Vertigo Vertigo x x x x x x x x x
Weight decreased Weight decreased x x x x x x x x x x x x x x x x x
Peripheral vascular disorder Peripheral vascular disorder x x x x x x x
Acute leukaemia Acute leukaemia x
Hypokinesia Hypokinesia x
Peripheral embolism Embolus leg x x x x x x x
Hypomagnesaemia Hypomagnesaemia x x
Injury Accidental injury x x x x x x x x x
Myocardial ischaemia Myocardial ischaemia x x x x x x x
Blood alkaline phosphatase increased Phosphatase alkaline increased x x x
Aspartate aminotransferase increased Aspartate aminotransferase increased x x x
Arterial thrombosis Arterial thrombosis x x x x x x x
Lung cancer metastatic Lung cancer metastatic x x x x x x x x x x x x
Malaise Sickness x x
Malaise x x
Discomfort Malaise x x
Ill-defined disorder Malaise x x
Frequent bowel movements Frequent bowel movements x
Blood bilirubin increased Blood bilirubin increased x x
Electrolyte imbalance Electrolyte imbalance x
Akathisia Akathisia x x x x x x x
Gait disturbance Gait disturbance x x
Blood creatinine increased Serum creatinine increased x x
Palmar-plantar erythrodysaesthesia syndrome Hand and foot syndrome secondary to sickle cell anaemia 0% - 20.3% x x x x x x x x
Hand and foot syndrome secondary to sickle cell anaemia Hand and foot syndrome secondary to sickle cell anaemia 0% - 20.3% x x x x x x x x
Neutropenic sepsis Neutropenic sepsis x x x x x x x x x x x x x x x x x x
Blood bilirubin abnormal Bilirubin abnormal x x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

IRINOTECAN

Side effects:31
Source:FDA Structured Product Label

IRINOTECAN

Side effects:49
Source:FDA Structured Product Label

IRINOTECAN

Side effects:49
Source:FDA Structured Product Label

Irinotecan

Side effects:51
Source:BC Cancer

IRINOTECAN

Side effects:56
Source:FDA Structured Product Label

IRINOTECAN

Side effects:56
Source:FDA Structured Product Label

IRINOTECAN

Side effects:56
Source:FDA Structured Product Label

IRINOTECAN HYDROCHLORIDE / CAMPTOSAR

Side effects:61
Source:FDA

IRINOTECAN

Side effects:73
Source:FDA Structured Product Label

Irinotecan

Side effects:76
Source:FDA Structured Product Label

irinotecan

Side effects:77
Source:FDA Structured Product Label

IRINOTECAN HYDROCHLORIDE / CAMPTOSAR

Side effects:77
Source:FDA

IRINOTECAN

Side effects:81
Source:FDA Structured Product Label

Irinotecan

Side effects:86
Source:FDA Structured Product Label

irinotecan HCI injection / Camptosar

Side effects:87
Source:FDA

IRINOTECAN HYDROCHLORIDE / CAMPTOSAR INJECTION

Side effects:96
Source:Health Canada

IRINOTECAN HYDROCHLORIDE / CAMPTOSAR

Side effects:99
Source:FDA

Irinotecan hydrochloride / IRINOTECAN ALPHAPHARM

Side effects:115
Source:medicines.org.au

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label